Statins and antihypertensives narrow BMI-linked gaps in blood pressure and cholesterol after age 40

The NCD Risk Factor Collaboration pooled 110 datasets to track systolic blood pressure and non-HDL cholesterol by BMI and age. In the 60- and 70-year-old cohorts, overweight and obese groups experienced steeper declines, reaching parity or advantage by 2024, coinciding with 70-72 percent medication uptake versus 40-48 percent in normal-BMI peers. Absolute differences shrank by 4-6 mmHg and 0.4-0.6 mmol/L more in higher-BMI strata. Younger adults under 40 showed no convergence, reflecting minimal screening and prescribing regardless of BMI.

This pattern illustrates how generic cardiovascular drugs, costing roughly $100 yearly, have quietly decoupled obesity from two major risk factors in middle and older age. The observational design cannot prove causation yet aligns with expanded statin and antihypertensive indications since the late 1990s. It also highlights a missed opportunity: early metabolic harm in young adults persists while older cohorts benefit from reactive pharmacotherapy. Future work must link these risk-factor shifts to hard endpoints such as myocardial infarction and heart-failure incidence.

Next studies should examine whether the same attenuation appears for diabetes incidence or microvascular disease and whether GLP-1 receptor agonists further compress remaining gaps. Registries tracking medication initiation by age and BMI will clarify prescribing thresholds and equity across income settings.